Date:11/6/2009

34) Interest income 3 212 48 1,001 Interest expense (52) (183) (240) (640) Other income (expense), net -- (12) 10 26 --- --- --- --- Net loss $(6,756) $(6,313) $(16,789) $(21,247) ======= ======= ======== ======== Basic and diluted net loss per share $(0.38) $(0.36) $(0.95) $(1.21) ====== ====== ====== ====== Shares used to compute basic and diluted net loss per share 17,617,209 17,538,886 17,588,832 17,508,094 ========== ========== ========== ========== Non-cash stock-based compensation expense included in operating expenses: (1) Research and development $148 $183 $596 $597 (2) General and administrative 576 190 1,025 570 ---- ---- ------ ------ $724 $373 $1,621 $1,167 ==== ==== ====== ======

                           NEUROGESX, INC.
               Condensed Consolidated Balance Sheets
                           (in thousands)

                                               September 30,   December 31,
                                                   2009            2008
                                               -------------   ------------
                                                 (unaudited)        (1)
                                                 -----------        ---
                           Assets
     Current assets:
       Cash and cash equivalents                     $48,468        $10,435
       
'/>"/>
SOURCE  NeurogesX
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 
Related biology technology :

1. NeurogesX to Present at Two November Conferences
2. NeurogesX to Present at UBS Global Life Sciences Conference
3. NeurogesX to Present at Upcoming Fall Conferences
4. NeurogesX Appoints New Board Director and Audit Committee Chairman
5. NeurogesX Reports Second Quarter 2009 Results
6. NeurogesX Announces New PDUFA Date for Qutenza(TM) New Drug Application
7. NeurogesX to Hold Conference Call to Discuss Second Quarter 2009 Financial Results
8. NeurogesX Added to Russell 3000 Index
9. NeurogesX Provides U.S. Regulatory Update for Qutenza(TM)
10. NeurogesX to Present at Needham Life Sciences Conference
11. NeurogesX Receives European Commission Approval for Qutenza(TM)